Search

Your search keyword '"Bavbek, Sevim"' showing total 445 results

Search Constraints

Start Over You searched for: Author "Bavbek, Sevim" Remove constraint Author: "Bavbek, Sevim"
445 results on '"Bavbek, Sevim"'

Search Results

1. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)

2. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

5. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

7. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

9. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

10. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper.

12. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma

13. Multi-country self-controlled study of exacerbation rates in severe asthma patients treated with mepolizumab: NEST interim analysis

14. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults

17. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey

19. Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group.

22. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

27. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

28. Allergies and COVID-19 vaccines : An ENDA/EAACI Position paper

29. Allergies and COVID-19 vaccines:An ENDA/EAACI Position paper

32. Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper

33. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

37. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper

43. Hypersensitivity reactions to biologicals: An EAACI position paper

44. COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations

46. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity

47. Change in allergy practice during the COVID-19 pandemic

48. Microbiota- the unseen players in adult asthmatic airways

50. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.

Catalog

Books, media, physical & digital resources